Ultima Genomics
PrivateLast Round
Early Funding
May 31, 2022
Total Funding Raised
$604.45M
Company Overview
Ultima Genomics is a biotechnology company that develops and manufactures high-throughput, low-cost genome sequencing platforms.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Biotech Equipment, Precision Medicine
Business Model
B2B
Customer Profile
Hardware Sales, Usage-Based SaaS
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ultima Genomics Comparables
Compare Ultima Genomics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Element Biosciences | 88% | |
| MGI | 78% | |
| GeneMind Biosciences Co., Ltd. | 77% |
For institutional investors. Book with your work email.
Ultima Genomics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | May 31, 2022 | ||||
| Grant | Apr 1, 2021 |
For institutional investors. Book with your work email.
Secondary Market Activity
Bids, offers, and trades by month
| Operation | Date | Price | Size | Share Class | Structure |
|---|---|---|---|---|---|
OFFER |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Ultima Genomics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Andreessen Horowitz | Early Funding |
| Khosla Ventures | Early Funding, Seed |
| NIH RADx | Grant |
| Playground Global | Early Funding |
| Founders Fund | Early Funding |
| D1 Capital Partners | Early Funding |
| aMoon | Early Funding |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 26, 2026
Launched the UG200 Series, a next-generation sequencing platform.
- Feb 25, 2026
Presented technologies at the AGBT Conference on February 25, 2026.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withNov 3, 2026
On Nov 2nd '26, Ultima Genomics plans to partner with QIAGEN, alongside Lucence, to support the SG-INSIGHT study under Phase III of Singapore's National Precision Medicine program.
- partners_withNov 3, 2026
Ultima Genomics plans to partner with Lucence Health Inc. to support Phase III of Singapore’s National Precision Medicine program, including the SG-INSIGHT study, in Singapore in Nov '26.
- attends_eventOct 20, 2026
Ultima Genomics attends ASHG 2026, where it launches paired-end sequencing on the UG200 Series and Solaris 2.0 Max workflows delivering up to 20 billion reads per wafer.
- launchesOct 20, 2026
Ultima Genomics launches Solaris 2.0 Max consumables and paired-end sequencing at ASHG 2026 on Oct 20th '26, with workflows delivering up to 20 billion reads per wafer and enabling what the company calls a $60 genome.
- launchesOct 20, 2026
At ASHG 2026, Ultima Genomics launches paired-end sequencing for its UG200 Series and makes Solaris 2.0 Max workflows available, delivering up to 20 billion reads per wafer and supporting what the company calls a $60 genome.
For institutional investors. Book with your work email.
Ultima Genomics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Ultima Genomics's valuation, stock price, and market status.
Is Ultima Genomics a public or private company?
Ultima Genomics is a private company.
What is the current stock price of Ultima Genomics?
Ultima Genomics is a private company, so its shares have no public market price. Caplight tracks Ultima Genomics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Ultima Genomics worth (valuation)?
Valuation information for Ultima Genomics is not publicly available.
Can I buy Ultima Genomics stock?
Ultima Genomics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Ultima Genomics's last funding round?
Ultima Genomics's most recent funding round was Early Funding on May 31, 2022.
Who are the main investors in Ultima Genomics?
Key investors in Ultima Genomics include Khosla Ventures, Playground Global, Lightspeed Venture Partners.
Will Ultima Genomics IPO soon?
No public IPO plans have been announced for Ultima Genomics.
How can I track Ultima Genomics secondary market activity?
Caplight tracks bids, offers, and trades in Ultima Genomics's shares on secondary markets.